

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 – 67 (Canceled)

68. (Currently Amended) A method for identifying a compound which ~~downmodulates an interaction between a first mammalian KRC polypeptide and a second mammalian GATA3 polypeptide to thereby downmodulate~~ downmodulates transcription of at least one Th2 cell differentiation cytokine gene comprising:

(a) providing an indicator composition comprising a ~~first~~ mammalian polypeptide comprising a Kappa Recognition Component (KRC) polypeptide and a ~~second~~ mammalian GATA3 polypeptide;

(b) contacting the indicator composition with each member of a library of test compounds; and

(c) selecting from the library of test compounds a compound of interest that downmodulates the ability of the ~~first~~ mammalian KRC polypeptide and the ~~second~~ mammalian GATA3 polypeptide to interact as compared to an appropriate control; ~~to thereby identify a compound which downmodulates an interaction between a first mammalian KRC polypeptide and a second mammalian GATA3 polypeptide and~~

(d) further comprising testing the ability of a compound identified in step (c) to thereby downmodulate transcription of at least one Th2 cytokine gene cell differentiation and selecting a compound which downmodulates Th2 cell differentiation to thereby identify a compound which downmodulates Th2 cell differentiation.

69. (Withdrawn) The method of claim 68, wherein the indicator composition is a cell cultured in vitro and further comprising determining the ability of the compound to downmodulate transcription of at least one Th2 cytokine gene.

Claim 70 (Canceled)

71. (Previously Pending) The method of claim 68, wherein the indicator composition is a mammalian cell cultured in vitro and KRC polypeptide is endogenous to the cell.

72. (Withdrawn) The method of claim 68, wherein the indicator composition is a cell cultured in vitro and the KRC polypeptide is heterologous to the cell.

73. (Previously Pending) The method of claim 68, wherein the indicator composition is a mammalian cell cultured in vitro and the GATA3 polypeptide is endogenous to the cell.

74. (Withdrawn) The method of claim 68, wherein the indicator composition is a cell cultured in vitro and the GATA3 polypeptide is heterologous to the cell.

75. (Withdrawn) The method of claim 68, wherein the indicator composition is a cell cultured in vitro and the KRC polypeptide and the GATA3 polypeptide are heterologous to the cell.

76. (Withdrawn) The method of claim 75, wherein the cell is a mammalian cell.

77. (Withdrawn) The method of claim 68, wherein the indicator composition is a cell and determining the ability of the test compound to modulate the interaction of the first polypeptide and the second polypeptide comprises determining the ability of the compound to modulate expression of a reporter gene in the cell.

78. (Previously Pending) The method of claim 68, wherein determining the ability of the test compound to modulate the interaction of the first polypeptide and the second polypeptide comprises determining the ability of the test compound to modulate the coimmunoprecipitation of the first polypeptide and the second polypeptide.

79. (Withdrawn) The method of claim 68, wherein the KRC polypeptide is encoded by the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1.

80. (Previously Pending) The method of claim 68, wherein the KRC polypeptide comprises the amino acid sequence of SEQ ID NO:2.

81. (Previously Pending) The method of claim 68, wherein the at least one Th2 cytokine gene is selected from the group consisting of IL-4, IL-5, and IL-13.